latest update:
[TrialBase DB]

trial summary · NCT06904066

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies

Trial record from the TrialBase DB dataset, status RECRUITING, condition Malignancy, Hematologic, sponsored by National Cancer Institute (NCI). Facts below are exported values from the current release, not inferred or edited prose.

registry NCT06904066phase PHASE1enrollment 86start 2026-11-04

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the cancer cells to create substances called neoepitopes. Researchers want to test a method of treating blood cancers by altering a person s T cells (a type of immune cell) to target neoepitopes. Objective: To test the use of neoepitope-specific T cells in people with blood cancers Eligibility: People aged 18 with any of 9 blood cancers. Design: Participants will have a bone marrow biopsy: A sample of soft tissue will be removed from inside a pelvic bone. This is needed to confirm their diagnosis and the TP53 and RAS mutations in their cancer cells. They will also have a skin biopsy to look for these mutations in other tissue. Participants will undergo apheresis: Blood will be taken from their body through a vein. The blood will pass through a machine that separates out the T cells. The remaining blood will be returned to the body through a different vein. The T cells will be grown to become neoepitope-specific T cells. Participants receive drugs for 3 days to prepare their body for the treatment. The modified T cells will be given through a tube inserted into a vein. Participants will need to remain in the clinic at least 7 days after treatment. Participants will have 8 follow-up visits in the first year after treatment. They will have 6 more visits over the next 4 years. Long-term follow-up will go on for 10 more years.

Source record: https://clinicaltrials.gov/study/NCT06904066

Facts

registry idNCT06904066
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionMalignancy, Hematologic
sponsorNational Cancer Institute (NCI)
sponsor classNIH
enrollment86
start date2026-11-04
primary completion2029-04-30
completion2029-04-30
results postednot reported

Conditions

  • Malignancy, Hematologic
  • Neoplasms, Hematologic
  • Neoplasms, Hematopoietic
  • Blood Cancer
  • Hematological Neoplasms
  • Hematopoietic Malignancies
  • Dysmyelopoietic Syndromes
  • Hematopoetic Myelodysplasia
  • Myeloid Leukemia, Acute
  • Nonlymphoblastic Leukemia, Acute
  • Leukemia, Lymphocytic, Acute

Interventions

  • aldesleukin
  • cyclophosphamide
  • fludarabine phosphate
  • Individual Patient TCR-Transduced PBL
  • TruSight Oncology (TSO) 500

Countries

  • United States

Intervention types: BIOLOGICAL, DEVICE, DRUG

Work with this record